Shandong Dyck Biotech Co., Ltd., established in 2018 and located in the Linshu Chemical Industry Park in Linyi, China, is a premier manufacturer and trading company specializing in imidazole and its derivatives. As a leading enterprise in its sector, the company operates a large-scale production facility with an annual output value exceeding US$100 million. Their extensive product portfolio includes high-capacity production of Imidazole (5,000t/a), N-methylimidazole (2,000t/a), N-ethylimidazole (1,600t/a), and various other specialized compounds such as 2-Methylimidazole, ionic liquids, and electrolytes. These products serve as critical raw materials across multiple high-tech industries, including electronics, where they function as epoxy resin curing agents and antirust agents for printed circuit boards. In the pharmaceutical sector, their chemicals are essential intermediates for antifungal, antimold, and bronchial asthma medications. Additionally, the company provides materials for green solvents and electric vehicle electrolytes. Shandong Dyck Biotech employs between 201 and 300 professionals, including a dedicated R&D team of over 50 people focused on maintaining advanced, environmentally friendly production technologies. They offer flexible business solutions including ODM, contract manufacturing, and buyer label options to meet diverse international requirements.